Clinical trials · Denver, CO
Muscle Invasive Bladder Urothelial Carcinoma clinical trials in Denver
We’re tracking 11 recruiting muscle invasive bladder urothelial carcinoma studies with a site in or near Denver — including Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Denver
- NCT07097142RecruitingPhase 3
Shorter radiation for bladder cancer with chemo
This trial tests if a shorter course of radiation therapy works as well as the usual longer course for people with bladder cancer who are also receiving standard chemotherapy. The goal is to see if shorter treatment can reduce side effects while still being effective.
Denver, ColoradoAges 18 years+ - NCT07061964RecruitingPhase 2
Immunotherapy and radiation to save the bladder
This trial tests whether combining immunotherapy and low-dose radiation after chemotherapy can help you avoid bladder removal. It's for people whose muscle-invasive bladder cancer has shrunk significantly after initial treatment.
Denver, ColoradoAges 18 years+ - NCT05987241RecruitingPhase 2/Phase 3
Using a blood test to guide immunotherapy after bladder/kidney cancer surgery
This study tests whether a blood test that detects tumor DNA can help guide the use of immunotherapy (nivolumab with or without relatlimab) after surgery for urothelial cancer. The goal is to see if starting immunotherapy based on the blood test results can prevent the cancer from coming back.
Denver, ColoradoAges 18 years+ - NCT04628767RecruitingPhase 2/Phase 3
Durvalumab plus chemo before surgery for upper tract cancer
This trial tests whether adding an immunotherapy drug (durvalumab) to chemotherapy before surgery can improve outcomes for people with high-grade upper tract urothelial cancer. It compares different treatment approaches based on whether a patient can receive cisplatin chemotherapy.
Denver, ColoradoAges 18 years+ - NCT06545955RecruitingPhase 3
Gene therapy study for high-grade bladder cancer not responding to BCG
This trial tests a gene therapy called nadofaragene firadenovec, given directly into the bladder, either alone or with chemo or immunotherapy. It's for people with high-grade bladder cancer that hasn't gone away after BCG treatment.
Denver, ColoradoAges 18 years+ - NCT06510374RecruitingPhase 3
Gene therapy vs. observation for intermediate risk bladder cancer
This trial tests a new gene therapy called nadofaragene firadenovec versus just watching and waiting (observation) for people with a specific type of bladder cancer that hasn't grown into the muscle. The goal is to see if the gene therapy can help keep the cancer from coming back.
Denver, ColoradoAges 18 years+ - NCT06567743RecruitingPhase 2
Study of a new virus therapy for high-risk bladder cancer
This trial tests a new virus-based medicine, cretostimogene grenadenorepvec, given directly into the bladder for people with high-risk non-muscle-invasive bladder cancer. It may help prevent the cancer from coming back, especially for those who have not had BCG treatment or whose cancer did not respond to BCG.
Lakewood, ColoradoAges 18 years+ - NCT06919965RecruitingPhase 3
TAR-210 vs. standard bladder chemo for high-risk bladder cancer
This trial compares a new drug called TAR-210, given directly into the bladder, to standard chemotherapy for people with a specific type of high-risk bladder cancer that has not invaded muscle. It tests if TAR-210 can be more effective with fewer side effects.
Lakewood, ColoradoAges 18 years+ - NCT06319820RecruitingPhase 3
TAR-210 vs standard bladder chemo for FGFR-mutated bladder cancer
This trial compares a new drug, TAR-210, which is placed directly into the bladder, against standard chemotherapy given through a catheter. It is for people with a specific type of bladder cancer that has a change in the FGFR gene.
Lakewood, ColoradoAges 18 years+ - NCT07566156RecruitingPhase 3
New drug combination vs. radiation for bladder cancer preservation
This trial tests whether two drugs (enfortumab vedotin and pembrolizumab) work better than radiation with chemotherapy for muscle-invasive bladder cancer. The goal is to treat your cancer while keeping your bladder instead of removing it.
Aurora, ColoradoAges 18 years+ - NCT05562830RecruitingPhase 1/Phase 2
Study for bladder or urinary tract cancer after PD-1 failure
This Phase 1/2 study tests investigational cancer treatment(s) in people with locally advanced or metastatic urothelial cancer that has not responded to PD-1/PD-L1 immunotherapy. It may help by trying a new approach after prior checkpoint treatment has stopped working or the cancer returns.
Aurora, ColoradoAges 18 years+
Hear when a new Muscle Invasive Bladder Urothelial Carcinoma trial opens near Denver, CO
We’ll email you when one opens near Denver, CO — at most once a week, no account needed, unsubscribe anytime.
Muscle Invasive Bladder Urothelial Carcinoma trials in other cities
Where these studies are running near Denver
Institutions with a site for the recruiting muscle invasive bladder urothelial carcinoma studies listed above.
- UCHealth University of Colorado Hospital · 5 studies
- UCHealth Highlands Ranch Hospital · 4 studies
- UCHealth Lone Tree Health Center · 4 studies
- UCHealth Cherry Creek Medical Center · 3 studies
- UCHealth Greeley Hospital · 3 studies
- UCHealth Medical Center of the Rockies · 3 studies
- AdventHealth Medical Group · 2 studies
- Colorado Clinical Research · 2 studies
What taking part in a muscle invasive bladder urothelial carcinoma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting muscle invasive bladder urothelial carcinoma studies in Colorado.
Common questions
- Are there muscle invasive bladder urothelial carcinoma clinical trials near Denver?
- Yes. We're currently tracking 11 recruiting muscle invasive bladder urothelial carcinoma studies with a site near Denver, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a muscle invasive bladder urothelial carcinoma study near Denver?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Denver to take part?
- Not necessarily. These studies have a site near Denver, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a muscle invasive bladder urothelial carcinoma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New muscle invasive bladder urothelial carcinoma studies open near Denver regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.